-
公开(公告)号:CR10473A
公开(公告)日:2009-01-12
申请号:CR10473
申请日:2008-11-28
Applicant: ABBOTT LAB
Inventor: DART MICHAEL J , CARROL WILLIAM A , FLORJANCIC ALAN S , FROST JENNIFER M , GALLAGHER MEGAN E , LI TONGMEI , NELSON DEREK W , PATEL MEENA V , PEDDI SRIDHAR , PEREZ-MEDRANO ARTURO , RYTHER KEITH B , TIETJE KARIN ROSEMARIE , KOLASA TEODOZYJ
IPC: A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , A61P29/00 , C07D277/46 , C07D277/48 , C07D277/60 , C07D277/82 , C07D417/06 , C07D417/12 , C07D417/14 , C07D513/04
Abstract: Compuestos de la formula (I), o sales farmaceuticas, prodrogas, sales de prodrogas, o combinaciones de los mismos, donde R1, R2, R3, R4 y L1 se definen en la memoria descriptiva, composiciones que comprenden dichos compuestos, y metodos para tratar condiciones y trastornos usando dichos compuestos y composiciones. La presente invencion tambien se refiere a compuestos de formula (II) o sales farmaceuticas, prodrogas, sales de prodrogas, o combinaciones de los mismos, donde R1a, R2a y Rxn tienen los valores definidos en la memoria descriptiva, composiciones que comprenden dichos compuestos, y metodos para tratar condiciones y trastornos usando dichos compuestos y composiciones.
-
公开(公告)号:NO20085385L
公开(公告)日:2008-12-29
申请号:NO20085385
申请日:2008-12-29
Applicant: ABBOTT LAB
Inventor: RYTHER KEITH B , KOLASA TEODOZYJ , PATEL MEENA V , DART MICHAEL J , CARROLL WILLIAM A , FLORJANCIC ALAN S , FROST JENNIFER M , GALLAGHER MEGAN E , LI TONGMEI , NELSON DEREK W , PEDDI SRIDHAR , PEREZ-MEDRANO ARTURO , TIETJE KARIN ROSEMARIE
IPC: C07D277/28
Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L1 are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
-
公开(公告)号:CA2628260A1
公开(公告)日:2007-05-18
申请号:CA2628260
申请日:2006-11-02
Applicant: ABBOTT LAB
Inventor: CARROLL WILLIAM A , PEREZ-MEDRANO ARTURO , LI TONGMEI
IPC: C07D231/38 , A61K31/415 , A61K31/416 , A61K31/4162 , A61K31/4439 , A61P29/00 , C07D231/54 , C07D401/12 , C07D495/04
Abstract: A compound having formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined in the description, is disclosed as an P2X 7 antagonist. Methods and compositions for treating disease or condition modulated by P2X 7 are also disclosed.
-
公开(公告)号:MXPA06012595A
公开(公告)日:2007-05-09
申请号:MXPA06012595
申请日:2005-04-28
Applicant: ABBOTT LAB
Inventor: HIRST GAVIN C , LI TONGMEI , CARROLL WILLIAM A , PEREZ-MEDRANO ARTURO , FLORJANCIC ALAN S , NELSON DEREK W , PEDDI SRIDHAR , BUNNELLE ERIC M , LI BIQIN
IPC: C07D257/06 , A61K31/00 , A61K31/41 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D487/04 , C07D491/04 , C07D491/18
Abstract: Se describe un compuesto que tiene la Formula (I) o Formula (II) como un antagonista de P2X7, en donde A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4 y R5, son como se definen en la descripcion. Se describen metodos y composiciones para tratar enfermedad o condicion modulada por P2X7.
-
公开(公告)号:SA1686B1
公开(公告)日:2007-01-27
申请号:SA01220565
申请日:2001-12-02
Applicant: ABBOTT LAB
Inventor: CLAIBORN AKIYO K , GWALTNEY STEPHEN L , HASVOLD LISA A , LI QUN , LI TONGMEI , GIN NAN- HORNG , MANTEI ROBERT A , ROCKWAY TODD W , SHAM HING L , SULLIVAN GERARD M , TONGG YUNSONG , WANG RAY T , WANG LE , WANG XILU , WANG WEIBO
IPC: A61K31/4164 , A61K31/4178 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/64 , C07D277/20 , C07D277/30 , C07D401/12 , C07D405/12 , C07D409/12
Abstract: الملخص: يتعلقالاختراعالراهنبمركباتإيميدازول imidazoles وثيازول thiazoles تحملبدائللهاالصيغةوطرقلتثبيطأنزيمنقلالفارنسيلfranesylransferase فيمريض.وهيمفيدةلتثبيطأنزيمنقلالفارنسيلكمايتعلقالاختراعبتراكيبسطأنزيمنقلالفارنسيل franesyltransferase
-
公开(公告)号:CA2470214A1
公开(公告)日:2003-06-26
申请号:CA2470214
申请日:2002-12-12
Applicant: ABBOTT LAB
Inventor: HUTCHINS CHARLES , GIRANDA VINCENT L , GONG JIANCHUN , STOLL VINCENT S , ABRAMS JASON N , DINGES JURGEN , ZHU GUI-DONG , DIEBOLD ROBERT , SONG XIAOHONG , ROSENBERG SAUL H , FISCHER JOHN P , LI QUN , GANDHI VIRAJ , WOODS KEITH W , PACKARD GARRICK , THOMAS SHEELA A , LI TONGMEI
IPC: C07D239/48 , A61K31/416 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/455 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/502 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/5377 , A61P35/00 , A61P43/00 , C07D213/63 , C07D213/65 , C07D213/75 , C07D213/82 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D473/34 , C07D475/02 , C07D495/04 , C07D498/04
Abstract: Compounds having the formula (I), are useful for inhibiting protein kinases and for the treatment of cancer. Also disclosed are compositions which inhib it protein kinases and methods of inhibiting protein kinases in a patient.
-
公开(公告)号:PE20020687A1
公开(公告)日:2002-08-03
申请号:PE2001001198
申请日:2001-11-29
Applicant: ABBOTT LAB
Inventor: CLAIBORNE AKIYO K , GWALTNEY II STEPHEN L , LI QUN , LIN NAN-HORNG , ROCKWAY TODD W , SULLIVAN GERARD M , WANG GARY T , WANG XILU , WANG WEIBO , WANG LE , TONG YUNSONG , SHAM HING L , MANTEI ROBERT A , LI TONGMEI , HASVOLD LISA A
IPC: A61K31/4164 , A61K31/4178 , A61K31/426 , A61K31/4439 , A61K31/4709 , A61P35/00 , A61P43/00 , C07D233/54 , C07D233/64 , C07D277/20 , C07D277/30 , C07D401/12 , C07D405/12 , C07D409/12 , C07D401/01
Abstract: SE REFIERE A IMIDAZOLES Y TIAZOLES DE FORMULA I DONDE E ES UN ANILLO CARBOCICLICO AROMATICO O NO AROMATICO DE CINCO, SEIS O SIETE MIEMBROS DONDE ENTRE 0-3 ATOMOS DE CARBONO ESTAN REEMPLAZADOS POR NITROGENO; F Y G SON C Y N CON LA SALVEDAD DE QUE CUANDO UNO DE F Y G ES N EL OTRO ES C; L1 Y L2 SON ALQUENILENO, ALQUINILENO, O, NR9, C(O), S, ENTRE OTROS; X ES S, NR7; R1 ES ARILO, ARILALQUILO, HETEROCICLO, (HETEROCICLO)ALQUILO; R2 ES H, ALCOXI, ALQUILO, AMINO, AMINOALQUILO, CIANO, CIANOALQUILO, ENTRE OTROS; R3 ES ARILO, HETEROCICLO Y CICLOALQUILO; R4-R6 SON H, NR9C(O), C(N)NR9, ALCANOILO, ALQUENILO, ENTRE OTROS; R7 ES H, ALQUILO, ARILO, CICLOALQUILO, ENTRE OTROS; R9 ES H, ALCOXIALQUILO, ALQUILO, AMIDOALQUILO, ENTRE OTROS; R12 ES H, ALCOXI, ALQUILO, ENTRE OTROS; m, n, p, q SON 0-4. SON COMPUESTOS PREFERIDOS 4-(((6-CLORO-2-(3-CLOROFENIL)-3-PIRIDINIL)METOXI)(1-METIL-1H-IMIDAZOL-5-IL)METIL)BENZONITRILO, 4-(((2-(3-CLOROFENIL)-6-METIL-3-PIRIDINIL)METOXI)(1-METIL-1H-IMIDAZOL-5-IL)METIL)BENZONITRILO, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA FARNESIL TRANSFERASA Y SON UTILES PARA EL TRATAMIENTO DE TUMORES
-
公开(公告)号:BRPI0712720A2
公开(公告)日:2012-11-20
申请号:BRPI0712720
申请日:2007-05-30
Applicant: ABBOTT LAB
Inventor: DART MICHAEL J , CARROLL WILLIAM A , FLORJANCIC ALAN S , FROST JENNIFER M , GALLAGHER MEGAN E , LI TONGMEI , NELSON DEREK W , PATEL MEENA V , PEDDI SRIDHAR , PEREZ-MEDRANO ARTURO , RYTHER KEITH B , TIETJE KARIN ROSEMAIRE , KOLASA TEODOZYJ
IPC: C07D277/46 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/429 , A61P29/00 , C07D277/48 , C07D277/60 , C07D277/82 , C07D417/06 , C07D417/12 , C07D417/14 , C07D513/04
Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L1 are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
-
公开(公告)号:PE20110804A1
公开(公告)日:2011-11-30
申请号:PE2011000626
申请日:2009-09-16
Applicant: ABBOTT LAB
Inventor: CARROLL WILLIAM A , DART MICHAEL J , FROST JENNIFER M , LATSHAW STEVEN P , KOLASA TEODOZYJ , LI TONGMEI , PEDDI SRIDHAR , LIU BO , PEREZ-MEDRANO ARTURO , PATEL MEENA , WANG XUEQING , NELSON DEREK W
IPC: C07D231/40 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14
Abstract: SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE X4 ES O, S, S(O), N(Rbx); Rbx ES H, ALQUILO, -C(O)O(ALQUILO); A1 ES -(CR1aR1b)q1-A2, -(CR1aR1b)q1-G1c, ENTRE OTROS; R1a Y R1b SON CADA UNO H, HALOGENO, ALQUILO C1-C4, ALQUILO C1-C4, ENTRE OTROS q1 ES 1-4; G1c ES CICLOALQUENILO, HETEROCICLO, ARILO, HETEROARILO; A2 ES -CO, -SO2, ENTRE OTROS; A5 ES DE PREFERENCIA PIRAZOL, 1,3,4-TIADIAZOL, ENTRE OTROS; RX ES C1-C4 ALQUILO, HALOGENO, NO2, ENTRE OTROS; z ES 0-4. SON COMPUESTOS PREFERIDOS: N-{(3E)-5-TERT-BUTIL-1-METIL-2-[(2R)-TETRAHIDROFURAN-2-ILMETIL]-1,2-DIHIDRO-3H-PIRAZOL-3-ILIDEN}-2-[(2R)-TETRAHIDROFURAN-2-ILMETOXI]-5-(TRIFLUOROMETIL)BENZAMIDA; N-[(2Z)-3-BUTIL-5-TERT-BUTIL-1,3,4-TIADIAZOL-2(3H)-ILIDEN]-2-(2-HIDROXI-2-METILPROPOXI)-5-(TRIFLUOROMETIL)BENZAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE PRESENTA UN BIODISPONIBILIDAD ORAL MAYOR O IGUAL A 30%. DICHOS COMPUESTOS SON LIGANDOS DE RECEPTORES DE CANNABINOIDES UTIL EN EL TRATAMIENTO DEL DOLOR
-
公开(公告)号:CA2700049A1
公开(公告)日:2009-04-16
申请号:CA2700049
申请日:2008-10-08
Applicant: ABBOTT LAB
Inventor: CARROLL WILLIAM A , PEREZ-MEDRANO ARTURO , DART MICHAEL J , NELSON DEREK W , KOLASA TEODOZY , FROST JENNIFER , LATSHAW STEVEN P , LI TONGMEI , LIU BO , PEDDI SRIDHAR , WANG XUEQING
IPC: C07D405/06 , A61K31/4155 , A61K31/422 , A61K31/427 , A61K31/443 , C07D413/06 , C07D417/06
Abstract: The present invention relates compounds of formula (I), as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.
-
-
-
-
-
-
-
-
-